Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase genes in Senegal

D. Ndiaye, Johanna P. Daily, O. Sarr, O. Ndir, O. Gaye, S. Mboup, D. F. Wirth

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Senegal recently (2004) switched to sulfadoxine-pyrimethamine (SP) with amodiaquine as first line therapy for malaria in response to increasing chloroquine resistance. In anticipation of emerging resistance to SP as a result of this change in drug pressure, we set out to define the baseline prevalence of SP-associated mutations in the dhfr and dhps genes in Plasmodium falciparum using geographically diverse and longitudinally collected samples. A total of 153 blood samples were analysed from patients (5 years or older) with mild malaria after informed consent was obtained. Longitudinal samples were collected between 2000 and 2003 in Pikine, a suburb of Dakar. Geographically diverse site sampling was carried out in 2003. The mutation prevalence in DHFR codons 51, 59 and 108 is 65%, 61% and 78% in Pikine, 2003. The overall prevalence of the triple mutation that is associated with high-level pyrimethamine resistance is 61%. The mutation prevalence rate in DHPS codons 436 and 437 is 21% and 40%, respectively. There is significant geographic variation in genotypic resistance, as samples from Pikine in 2003 had higher mutation prevalence in the pfdhfr and pfdhps genes compared to samples from Tambacounda (P < 0.015). In summary, this study demonstrates a high background prevalence of SP resistance mutations already present in P. falciparum in Senegal.

Original languageEnglish (US)
Pages (from-to)1176-1179
Number of pages4
JournalTropical Medicine and International Health
Volume10
Issue number11
DOIs
StatePublished - Nov 2005
Externally publishedYes

Fingerprint

Dihydropteroate Synthase
Senegal
Tetrahydrofolate Dehydrogenase
Plasmodium falciparum
Mutation
Genes
Codon
Malaria
Amodiaquine
Pyrimethamine
Chloroquine
Mutation Rate
Informed Consent
Pressure
pyrimethamine drug combination fanasil

Keywords

  • dhfr
  • dhps
  • Haplotypes
  • Senegal
  • Sulfadoxine-pyrimethamine

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Infectious Diseases
  • Parasitology
  • Immunology

Cite this

Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase genes in Senegal. / Ndiaye, D.; Daily, Johanna P.; Sarr, O.; Ndir, O.; Gaye, O.; Mboup, S.; Wirth, D. F.

In: Tropical Medicine and International Health, Vol. 10, No. 11, 11.2005, p. 1176-1179.

Research output: Contribution to journalArticle

Ndiaye, D. ; Daily, Johanna P. ; Sarr, O. ; Ndir, O. ; Gaye, O. ; Mboup, S. ; Wirth, D. F. / Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase genes in Senegal. In: Tropical Medicine and International Health. 2005 ; Vol. 10, No. 11. pp. 1176-1179.
@article{6ad5ec8260904da0b2a27512e9e5b41b,
title = "Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase genes in Senegal",
abstract = "Senegal recently (2004) switched to sulfadoxine-pyrimethamine (SP) with amodiaquine as first line therapy for malaria in response to increasing chloroquine resistance. In anticipation of emerging resistance to SP as a result of this change in drug pressure, we set out to define the baseline prevalence of SP-associated mutations in the dhfr and dhps genes in Plasmodium falciparum using geographically diverse and longitudinally collected samples. A total of 153 blood samples were analysed from patients (5 years or older) with mild malaria after informed consent was obtained. Longitudinal samples were collected between 2000 and 2003 in Pikine, a suburb of Dakar. Geographically diverse site sampling was carried out in 2003. The mutation prevalence in DHFR codons 51, 59 and 108 is 65{\%}, 61{\%} and 78{\%} in Pikine, 2003. The overall prevalence of the triple mutation that is associated with high-level pyrimethamine resistance is 61{\%}. The mutation prevalence rate in DHPS codons 436 and 437 is 21{\%} and 40{\%}, respectively. There is significant geographic variation in genotypic resistance, as samples from Pikine in 2003 had higher mutation prevalence in the pfdhfr and pfdhps genes compared to samples from Tambacounda (P < 0.015). In summary, this study demonstrates a high background prevalence of SP resistance mutations already present in P. falciparum in Senegal.",
keywords = "dhfr, dhps, Haplotypes, Senegal, Sulfadoxine-pyrimethamine",
author = "D. Ndiaye and Daily, {Johanna P.} and O. Sarr and O. Ndir and O. Gaye and S. Mboup and Wirth, {D. F.}",
year = "2005",
month = "11",
doi = "10.1111/j.1365-3156.2005.01506.x",
language = "English (US)",
volume = "10",
pages = "1176--1179",
journal = "Tropical Medicine and International Health",
issn = "1360-2276",
publisher = "Wiley-Blackwell",
number = "11",

}

TY - JOUR

T1 - Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase genes in Senegal

AU - Ndiaye, D.

AU - Daily, Johanna P.

AU - Sarr, O.

AU - Ndir, O.

AU - Gaye, O.

AU - Mboup, S.

AU - Wirth, D. F.

PY - 2005/11

Y1 - 2005/11

N2 - Senegal recently (2004) switched to sulfadoxine-pyrimethamine (SP) with amodiaquine as first line therapy for malaria in response to increasing chloroquine resistance. In anticipation of emerging resistance to SP as a result of this change in drug pressure, we set out to define the baseline prevalence of SP-associated mutations in the dhfr and dhps genes in Plasmodium falciparum using geographically diverse and longitudinally collected samples. A total of 153 blood samples were analysed from patients (5 years or older) with mild malaria after informed consent was obtained. Longitudinal samples were collected between 2000 and 2003 in Pikine, a suburb of Dakar. Geographically diverse site sampling was carried out in 2003. The mutation prevalence in DHFR codons 51, 59 and 108 is 65%, 61% and 78% in Pikine, 2003. The overall prevalence of the triple mutation that is associated with high-level pyrimethamine resistance is 61%. The mutation prevalence rate in DHPS codons 436 and 437 is 21% and 40%, respectively. There is significant geographic variation in genotypic resistance, as samples from Pikine in 2003 had higher mutation prevalence in the pfdhfr and pfdhps genes compared to samples from Tambacounda (P < 0.015). In summary, this study demonstrates a high background prevalence of SP resistance mutations already present in P. falciparum in Senegal.

AB - Senegal recently (2004) switched to sulfadoxine-pyrimethamine (SP) with amodiaquine as first line therapy for malaria in response to increasing chloroquine resistance. In anticipation of emerging resistance to SP as a result of this change in drug pressure, we set out to define the baseline prevalence of SP-associated mutations in the dhfr and dhps genes in Plasmodium falciparum using geographically diverse and longitudinally collected samples. A total of 153 blood samples were analysed from patients (5 years or older) with mild malaria after informed consent was obtained. Longitudinal samples were collected between 2000 and 2003 in Pikine, a suburb of Dakar. Geographically diverse site sampling was carried out in 2003. The mutation prevalence in DHFR codons 51, 59 and 108 is 65%, 61% and 78% in Pikine, 2003. The overall prevalence of the triple mutation that is associated with high-level pyrimethamine resistance is 61%. The mutation prevalence rate in DHPS codons 436 and 437 is 21% and 40%, respectively. There is significant geographic variation in genotypic resistance, as samples from Pikine in 2003 had higher mutation prevalence in the pfdhfr and pfdhps genes compared to samples from Tambacounda (P < 0.015). In summary, this study demonstrates a high background prevalence of SP resistance mutations already present in P. falciparum in Senegal.

KW - dhfr

KW - dhps

KW - Haplotypes

KW - Senegal

KW - Sulfadoxine-pyrimethamine

UR - http://www.scopus.com/inward/record.url?scp=27844540752&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27844540752&partnerID=8YFLogxK

U2 - 10.1111/j.1365-3156.2005.01506.x

DO - 10.1111/j.1365-3156.2005.01506.x

M3 - Article

VL - 10

SP - 1176

EP - 1179

JO - Tropical Medicine and International Health

JF - Tropical Medicine and International Health

SN - 1360-2276

IS - 11

ER -